- Home
- CHCT vs KURA Comparison
CHCT vs KURA Comparison
Compare CHCT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCT
- KURA
- Stock Information
- Founded
- CHCT 2014
- KURA 2014
- Country
- CHCT United States
- KURA United States
- Employees
- CHCT N/A
- KURA N/A
- Industry
- CHCT Real Estate Investment Trusts
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHCT Real Estate
- KURA Health Care
- Exchange
- CHCT Nasdaq
- KURA Nasdaq
- Market Cap
- CHCT 422.2M
- KURA 492.9M
- IPO Year
- CHCT 2015
- KURA N/A
- Fundamental
- Price
- CHCT $16.34
- KURA $5.69
- Analyst Decision
- CHCT Buy
- KURA Strong Buy
- Analyst Count
- CHCT 4
- KURA 12
- Target Price
- CHCT $21.00
- KURA $24.50
- AVG Volume (30 Days)
- CHCT 196.0K
- KURA 1.2M
- Earning Date
- CHCT 07-29-2025
- KURA 05-01-2025
- Dividend Yield
- CHCT 11.41%
- KURA N/A
- EPS Growth
- CHCT N/A
- KURA N/A
- EPS
- CHCT N/A
- KURA N/A
- Revenue
- CHCT $116,531,000.00
- KURA $67,991,000.00
- Revenue This Year
- CHCT $7.14
- KURA $171.90
- Revenue Next Year
- CHCT $7.04
- KURA $60.51
- P/E Ratio
- CHCT N/A
- KURA N/A
- Revenue Growth
- CHCT 1.33
- KURA N/A
- 52 Week Low
- CHCT $14.76
- KURA $5.41
- 52 Week High
- CHCT $27.62
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- CHCT 48.18
- KURA 42.98
- Support Level
- CHCT $15.62
- KURA $5.56
- Resistance Level
- CHCT $16.85
- KURA $5.84
- Average True Range (ATR)
- CHCT 0.39
- KURA 0.34
- MACD
- CHCT 0.02
- KURA -0.02
- Stochastic Oscillator
- CHCT 54.96
- KURA 20.39
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.